RBX1 Loss and CDK2 Inhibition in High-Grade Serous Ovarian Carcinoma Cells

A research paper from figshare, authored by Ally C. Farrell and last updated on 2026-04-28, details a study on tubo-ovarian, high-grade serous carcinoma. The work identifies CDK2 as a synthetic lethal interactor of RBX1, using siRNA and the drug SNS-032 in cell models, and reports selective cytotoxicity with lower EC50 values in RBX1-deficient cells.

Use Cases

• Investigating synthetic lethal interactions for RBX1-deficient tumors based on the described CDK2 inhibition experiments.
• Analyzing cell viability and cytotoxicity data from siRNA and SNS-032 treatments mentioned in the description.
• Studying mechanisms of DNA damage and apoptosis via γ-H2AX foci and cleaved Caspase-3 signals as described.
• Evaluating preclinical rationale for CDK2-targeted therapies in high-grade serous ovarian carcinoma.

Strengths

• The description provides specific biological findings, including that heterozygous RBX1 loss occurs in approximately 81% of HGSCs.
• Experimental results are detailed, citing specific cell lines (COV362 and OVCAR-3) and the drug SNS-032.
• The dataset is openly shared under a CC-BY-4.0 license, facilitating reuse.

Limitations

• The primary file is a 528.8 KB PDF, which likely contains the research article rather than structured, machine-readable data tables.
• Row count and column-level documentation are unknown, limiting suitability assessment for direct computational analysis.
• Description metadata is limited; actual data quality and availability require manual inspection after download.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from cell culture studies, as described in the paper.

Freshness

Last updated 2026-04-28 05:27:40; freshness should be verified.